Latest Breaking News On - Previously treated patients - Page 1 : comparemela.com

Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB -April 05, 2024 at 11:34 pm EDT

Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2.

Sobi to present new data at EAHAD 2024

Sobi® will present new data at the 17th European Association of Haemophilia and Allied Disorders conference in Frankfurt from 6-9 February 2024. The studies that will be presented support Sobi s.

Improvements in 'mood/emotions' reported for children on Altuviiio

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colo

− FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status or Prior Types of Therapies in More Than a Decade− FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free.

Takeda Receives U.S. FDA Approval of FRUZAQLA fruquintinib for Previously Treated Metastatic Colorectal Cancer

Takeda TSE4502NYSETAK today announced that the U.S. Food and Drug Administration FDA has approved FRUZAQLA fruquintinib an oral targeted therapy for adults with metastatic colorectal cancer mCRC who have been previously treated with fluoropyrimidine oxaliplatin and irinotecanbased chemotherapy an antiVEGF therapy and if RAS wildtype and medically appropriate an antiEGFR therapy.